(Total Views: 500)
Posted On: 02/20/2021 2:27:19 PM
Post# of 153905
Jlang,
I agree completely. Hard to design or recommend a therapy when the pathology is still largely a mystery.
With the SAE profile, I imagine leronlimab will eventually be tried off-label post approval in a slew of indications.
Small market, but I would love to see a trial for ALS.
I agree completely. Hard to design or recommend a therapy when the pathology is still largely a mystery.
With the SAE profile, I imagine leronlimab will eventually be tried off-label post approval in a slew of indications.
Small market, but I would love to see a trial for ALS.
(0)
(0)
